

## Condensed Consolidated Interim Statements of Position as of

	June 30, 2018 (Unaudited) NIS thousands	June 30, 2017 (Unaudited) NIS thousands	December 31, 2017 (Audited) NIS thousands
<b>Current assets</b>			
Cash and cash equivalents	71,293	17,580	5,040
Receivables and other debit balances	4,985	1,340	1,388
<b>Total current assets</b>	<b>76,278</b>	<b>18,920</b>	<b>6,428</b>
Long-term prepaid expenses	546	21	37
Long-term pledged deposits	212	-	-
Asset in respect of employee benefits, net	11	11	11
Property, plant and equipment, net	992	746	760
<b>Total non-current assets</b>	<b>1,761</b>	<b>778</b>	<b>808</b>
<b>Total assets</b>	<b>78,039</b>	<b>19,698</b>	<b>7,236</b>
<b>Current liabilities</b>			
Trade payables	10,887	720	559
Other payables and credit balances	12,308	8,095	8,254
Short-term employee benefits	1,616	745	536
Derivative instruments	19,921	-	-
<b>Total current liabilities</b>	<b>44,732</b>	<b>9,560</b>	<b>9,349</b>
<b>Non-current liabilities</b>			
Derivative instruments	23,838	-	-
<b>Total non-current liabilities</b>	<b>23,838</b>	<b>-</b>	<b>-</b>
<b>Total liabilities</b>	<b>68,570</b>	<b>9,560</b>	<b>9,349</b>
<b>Shareholders' equity</b>			
Share capital	-	-	-
Share premium	266,921	228,840	228,893
Capital reserve for translation differences	38	(31)	(133)
Capital reserve for share-based payments	11,695	5,699	7,183
Accumulated deficit	(269,185)	(224,370)	(238,056)
<b>Total shareholders' equity</b>	<b>9,469</b>	<b>10,138</b>	<b>(2,113)</b>
<b>Total liabilities and shareholders' equity</b>	<b>78,039</b>	<b>19,698</b>	<b>7,236</b>

**Condensed Consolidated Interim Statements of Income**

	<b>For the 6-month period ended</b>		<b>For the 3-month period ended</b>		<b>Year ended</b>
	<b>June 30,</b>	<b>June 30,</b>	<b>June 30,</b>	<b>June 30,</b>	<b>December 31,</b>
	<b>2018</b>	<b>2017</b>	<b>2018</b>	<b>2017</b>	<b>2017</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>	<b>(Unaudited)</b>	<b>(Unaudited)</b>	<b>(Audited)</b>
	<b>NIS thousands</b>	<b>NIS thousands</b>	<b>NIS thousands</b>	<b>NIS thousands</b>	<b>NIS thousands</b>
Research and development expenses	<b>15,194</b>	14,813	<b>6,588</b>	10,175	22,340
General and administrative expenses	<b>11,392</b>	5,530	<b>8,187</b>	2,632	11,374
<b>Operating loss</b>	<b>26,586</b>	20,343	<b>14,775</b>	12,807	33,714
Finance income	<b>(1)</b>	(84)	<b>(1)</b>	(83)	(5)
Finance expense	<b>3,146</b>	730	<b>2,884</b>	3	365
Finance expense (income), net	<b>3,145</b>	646	<b>2,883</b>	(80)	360
Loss before taxes on income	<b>29,731</b>	20,989	<b>17,658</b>	12,727	34,074
Taxes on income	<b>1,398</b>	556	<b>1,183</b>	346	1,157
<b>Loss for the period attributable to the shareholders of the Company</b>	<b>31,129</b>	21,545	<b>18,841</b>	13,073	35,231
<b>Ordinary loss per share (in NIS):</b>					
Basic and diluted loss	<b>3.2</b>	2.6	<b>1.9</b>	1.4	3.9
Number of shares used to compute basic and diluted loss per share (thousands of shares)	<b>9,646</b>	8,421	<b>9,679</b>	9,443	9,025